HSK42360

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Malignant Brain TumorsSolid Tumors

Phase 1

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

RecruitingNCT06536400

Haisco Pharmaceutical Group Co., Ltd.Solid Tumors

Start: 2024-06-25End: 2027-07-07Target: 316Updated: 2024-08-05

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

RecruitingNCT07158710

Haisco Pharmaceutical Group Co., Ltd.Malignant Brain Tumors

Start: 2025-08-15End: 2029-12-03Target: 159Updated: 2025-09-08

Related Papers

Abstract LB405: Novel brain-penetrant BRAF paradox breaker HSK42360 demonstrates promising antitumor activity in patients with BRAF-mutant glioma

Cancer Research2026-04-17

CTNI-28. PHASE 1 STUDY OF BRAIN-PENETRANT BRAF INHIBITOR HSK42360 IN ADULT PATIENTS WITH BRAF V600-MUTATED ADVANCED SOLID TUMORS OR RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

Neuro-Oncology2025-11-01

A phase 1, multicenter, open-label study of HSK42360, a brain-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.

Journal of Clinical Oncology2025-05-28